430 476
AMS, Pfizer, and Astellas; research grant from Coloplast; previous
chairman of the Scottish Pelvic Network, sponsored by various
industrial companies. Salvador Arlandis: researcher for Astellas,
Coloplast, and Ipsen; speaker and consultant for Astellas, Pfizer, Gebro,
and Medtronic. Ricarda Bauer: consultant, speaker, and researcher for
Boston Scientific and Promedon. Fiona Burkhard: speaker for Allergan
and consultant for Novartis. Linda Cardozo: Allergan, Astellas, BMR,
Pfizer, Pierre-Fabre, and Syner-Med. David Castro Diaz: speaker for
Astellas, Gebro, and Recordati; investigator for Astellas, Allergan, and
Ipsen. Christopher Chapple: consultant, speaker, and researcher for
Allergan, Astellas, Boston Scientific, Medtronic, and Recordati. Jean
Nicolas Cornu: consultant for Boston Scientific, Coloplast, EDAP-TMS,
Bouchara Recordati, Bard, Astellas, Pfizer, Takeda, and Allergan;
researcher for GSK, Coloplast, Allergan, and Cousin Biotech. Francisco
Cruz: speaker, consultant, and investigator for Allergan, Astellas, AMS,
Ipsen, Recordati, and Pfizer. Xavier Deffieux: consultant and speaker for
Allergan and B-Braun. Jan Deprest: consultant for AMS, Ethicon, Bard,
and Coloplast; researcher for Ethicon, Garrard and Blasingame Lawyers,
and Clayton Law. Alfons Gunnemann: speaker for Janssen, Coloplast,
and Bayer. Maria Gyhagen: speaker for Astellas. John Heesakkers:
consultant for Pierre Fabre, Astellas, and Bluewind; speaker for Astellas,
Allergan, Pierr Fabre, Boston and Scientific Int; research grants from
Astellas, Allergan, Boston Scientific, and Urogyn BV. Jan-Paul Roovers:
researcher for Coloplast, Tepha, Urogyn, and AMI; consultant for
Coloplast and Tepha; speaker for Astellas and Cogentix. Stefano
Salvatore: researcher for Astellas, Italfarmaco, Cynosure, and Shionogi;
consultant and speaker for Astellas, Allergen, Deka, Fidia, Shionogi, and
Coloplast. Frank Van der Aa: speaker for Astellas, GSK, and Ipsen;
investigator (unrestricted grants) for Astellas, Allergan, and Medtronic.
Walter Artibani, Heinz Koelbl, Sheila MacNeil, Alberto Milani, Gert
Naumann, Karl-Dietrich Sievert, and Tufan Tarcan: nothing to disclose.
Funding/Support and role of the sponsor:
None.
Acknowledgements:
This paper has also been influenced by discussions
during the meetings of the European Cooperation in Science and
Technology (COST) Biomedicine and Molecular Biosciences Action
BM1209 Regenerative Sphincter Therapy, funded by the European
Commission.
References
[1]
Slieker-ten Hove MCP, Pool-Goudzwaard AL, Eijkemans MJ, Stee- gers-Theunissen RP, Burger CW, Vierhout ME. Symptomatic pelvic organ prolapse and possible risk factors in a general population. Am J Obstet Gynecol 2009;200:184.e1–7.
[2]
Gyhagen M, Bullarbo M, Nielsen TF, Milsom I. Prevalence and risk factors for pelvic organ prolapse 20 years after childbirth: a national cohort study in singleton primiparae after vaginal or caesarean delivery. BJOG 2013;120:152–60.[3]
de Boer TA, Slieker-Ten Hove MC, Burger CW, Kluivers KB, Vierhout ME. The prevalence and factors associated with previous surgery for pelvic organ prolapse and/or urinary incontinence in a cross-sec- tional study in The Netherlands. Eur J Obstet Gynecol Reprod Biol 2011;158:343–9.[4]
Smith AR, Koelbl H. Is mid-urethral placement of synthetic minimal access tapes important in stress urinary incontinence surgery? Neurourol Urodyn 2010;29(4):676–8.[5]
Hannestad YS, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Nor- wegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. J Clin Epidemiol 2000;53:1150–7.[6]
Glazener C, Elders A, Macarthur C, et al. Childbirth and prolapse: long-term associations with the symptoms and objective measure- ment of pelvic organ prolapse. BJOG 2013;120:161–8.[7]
Gutman RE, Ford DE, Quiroz LH, Shippey SH, Handa VL, et al. Is there a pelvic organ prolapse threshold that predicts pelvic floor symp- toms? Am J Obstet Gynecol 2008;199:683.e1–7.[8]
Abdel-Fattah M, Familusi A, Fielding S, Ford J, Bhattacharya S. Primary and repeat surgical treatment for female pelvic organ prolapse and incontinence in parous women in the UK: a register linkage study. BMJ Open 2011;1:e000206.[9]
Denman MA, GregoryWT, Boyles SH, Smith V, Edwards SR, Clark AL. Reoperation 10 years after surgically managed pelvic organ pro- lapse and urinary incontinence. Am J Obstet Gynecol 2008;198:555.e1–5.[10]
Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta- analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.[11]
Labrie J, Berghmans BL, Fischer K, et al. Surgery versus physiother- apy for stress urinary incontinence. N Engl J Med 2013;369: 1124–33.
[12]
Lapitan MCM, Cody JD. Open retropubic colposuspension for uri- nary incontinence in women. Cochrane Database Syst Rev 2016;2:CD002912.[13]
Dean N, Ellis G, Wilson PD, Herbison GP. Laparoscopic colposus- pension for urinary incontinence in women. Cochrane Database Syst Rev 2006;3:CD002239.
[14]
Maher C, Feiner B, Baessler K, Christmann-Schmid C, Haya N, Brown J. Surgery for women with anterior compartment prolapse. Cochrane Database Syst Rev 2016;11:CD004014.
[15]
Novara G, Artibani W, Barber MD, et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol 2010;58:218–38.
[16]
Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. Cochrane Database Syst Rev 2014;12: CD003636.[17]
Rehman H, Bezerra CC, Bruschini H, Cody JD. Traditional subure- thral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2011;1:CD001754.
[18]
Albo ME, Richter HE, Brubaker L, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med 2007;356:2143–55.
[19]
Khan N, Abboudi H, Khan MS, Dasgupta P, Ahmed K. Measuring the surgical ‘‘learning curve’’: methods, variables and competency. BJU Int 2014;113:504–8.
[20]
Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2015;7:CD006375.
[21] SCENIHR. Final opinion on the safety of surgical meshes used in
urogynecological surgery; 2015.
http://ec.europa.eu/health/ scientific_committees/emerging/docs/scenihr_o_049.pdf.
[22]
Karmakar D, Mostafa A, Abdel-Fattah M. Long-term outcomes of transobturator tapes in women with stress urinary incontinence; E-TOT randomised controlled trial. BJOG 2017;124:973–81.[23]
Ulrich D, Tammaa A, Ho¨lbfer S, et al. Ten-year followup after tension-free vaginal tape-obturator procedure for stress urinary incontinence. J Urol 2016;196:1201–6.[24]
Serati M, Braga A, Athanasiou S, et al. Tension-free vaginal tape- obturator for treatment of pure urodynamic stress urinary inconti- nence: efficacy and adverse effects at 10-year follow-up. Eur Urol 2017;71:674–9.
[25] European Association of Urology. EAU guidelines on urinary incon-
tinence in adults. 2016
In: https://uroweb.org/wp-content/ uploads/EAU-Guidelines-Urinary-Incontinence-2016.pdf.[26]
Mostafa A, Lim CP, Hopper L, Madhuvrata P, Abdel-FattahM. Single- incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updatedE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 2 4 – 4 3 1
430